The total medical costs of cancers are about 5% of national health care expenditures and 10% of Medicare outlays. Much of what we know about cancer costs comes from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registries linked to Medicare claims (SEER- Medicare). While the SEER-Medicare link represents the experience of 85% of Aged Medicare beneficiaries enrolled in the fee-for-service (FFS) indemnity option, the link omits the experience of the 15% of seniors enrolled in Medicare HMOs. These groups differ: 1) HMO providers face different incentives;2) HMO Medicare beneficiaries generally have better benefits;3) given that FFS vs. HMO choice is voluntary, the 2 populations may differ in their health status and preferences in ways that are difficult to measure. In addition, utilization and costs for Medicare Working Aged beneficiaries may be under-reported in SEER-Medicare. These factors may cause selection and omission biases in cancer cost estimates based on ether group alone. Building on the Cancer Research Network, we will develop a multi-site, multi-payer database to support analyses extending and complementing the SEER-Medicare link by addressing 3 aims:
Aim 1 - Descriptive Analyses: Estimate the incremental medical care cost of all cancers, and selected cancers, broken down by cancer site, phase of treatment, stage at diagnosis, cancer type (fatal vs. non- fatal), patient demographics, co-morbidity, and source of health insurance for the years 2000-2007 in 4 large integrated health care systems.
Aim 2 - Omissions Bias: Estimate the costs of each cancer care component for Aged Medicare HMO beneficiaries that is omitted from SEER-Medicare: a) non-Medicare covered services;b) effects of health care for seniors whose cancers were diagnosed before age 65;c) cancer screening services;d) cancer prevention services;e) changes in benefits, if any, associated with switching from private health insurance to Medicare;and f) employer-covered benefits for Working Aged beneficiaries.
Aim 3 - Selection Bias: Estimate the incremental medical care costs of all cancers, as well as selected cancers, for SEER-Medicare over 2000-2007. Model the determinants of cancer costs across HMO and FFS systems for Medicare Aged beneficiaries, correcting for selection and omissions biases. We hypothesize that HMO/FFS system differences, benefit differences, and omissions biases will account for a larger proportion of cancer costs that those from selection biases. This study will update the information on the medical care costs of cancer for Aged Medicare beneficiaries. We will also learn how cancer care varies between Medicare's FFS and HMO options.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA114204-03S1
Application #
7909251
Study Section
Special Emphasis Panel (ZRG1-HOP-S (03))
Program Officer
Yabroff, Robin
Project Start
2009-08-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
3
Fiscal Year
2009
Total Cost
$343,694
Indirect Cost
Name
Kaiser Foundation Research Institute
Department
Type
DUNS #
150829349
City
Oakland
State
CA
Country
United States
Zip Code
94612
Lafata, Jennifer Elston; Salloum, Ramzi G; Fishman, Paul A et al. (2015) Preventive care receipt and office visit use among breast and colorectal cancer survivors relative to age- and gender-matched cancer-free controls. J Cancer Surviv 9:201-7
Hassett, Michael J; Uno, Hajime; Cronin, Angel M et al. (2015) Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care :
Ritzwoller, Debra P; Carroll, Nikki M; Delate, Thomas et al. (2014) Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience. J Thorac Oncol 9:692-701
Glazer, Evan S; Hornbrook, Mark C; Krouse, Robert S (2014) A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage 47:307-14
Loggers, Elizabeth T; Fishman, Paul A; Peterson, Do et al. (2014) Advanced imaging among health maintenance organization enrollees with cancer. J Oncol Pract 10:231-8
VanderWalde, Noam A; Salloum, Ramzi G; Liu, Tsai-Ling et al. (2014) Positron emission tomography and stage migration in head and neck cancer. JAMA Otolaryngol Head Neck Surg 140:654-61
Fishman, Paul A; Hornbrook, Mark C; Ritzwoller, Debra P et al. (2013) The challenge of conducting comparative effectiveness research in cancer: the impact of a fragmented U.S. health-care system. J Natl Cancer Inst Monogr 2013:99-105
O'Keeffe-Rosetti, Maureen C; Hornbrook, Mark C; Fishman, Paul A et al. (2013) A standardized relative resource cost model for medical care: application to cancer control programs. J Natl Cancer Inst Monogr 2013:106-16
Hornbrook, Mark C; Fishman, Paul A; Ritzwoller, Debra P et al. (2013) When does an episode of care for cancer begin? Med Care 51:324-9
Skeps, Raymond; McMullen, Carmit K; Wendel, Christopher S et al. (2013) Changes in body mass index and stoma related problems in the elderly. J Geriatr Oncol 4:84-9

Showing the most recent 10 out of 16 publications